Creo Medical Group PLC New video abstract featuring Speedboat published

TIDMCREO

Creo Medical Group PLC

24 April 2019

Creo Medical Group plc

("Creo" or the "Company")

New video abstract featuring Speedboat published

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that the Company's Speedboat device has featured in a newly published video abstract entitled, "A new approach to endoscopic submucosal tunneling dissection: the "Speedboat-RS2" device".

The video abstract has been published via an open access content publisher, Thieme Group. It is available in the Endoscopy E-videos section and can be viewed online here:

https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-0875-3352

The video abstract was authored by UK experts in the field of Gastrointestinal ("GI") therapeutic endoscopy and users of Creo's Speedboat device for colorectal endoscopic submucosal dissection, an advanced surgical procedure using endoscopy to remove gastrointestinal pre-cancerous lesions that have not entered the muscle layer.

The authors were:

- Dr Zacharias Tsiamoulos, Consultant Gastroenterologist at Queen Elizabeth the Queen Mother Hospital, East Kent

- Dr Joseph Sebastian, Consultant Gastroenterologist at Queen Elizabeth the Queen Mother Hospital, East Kent

- Dr Nipin Bagla, Consultant Histopathologist at Queen Elizabeth the Queen Mother Hospital, East Kent

   -      Professor Brian Saunders, Consultant Gastroenterologist at St. Mark's Hospital Foundation 
   -      Dr Chris Hancock, Founder and Chief Technology Officer, Creo Medical Group plc 

Craig Gulliford, Chief Executive Officer of Creo, commented:

"It is encouraging to see that additional case-studies of the effective clinical use of our Speedboat Device are being shared more and more widely amongst the Gastroenterological community. This video abstract provides another example of how our Speedboat technology provides precise dissection and controlled haemostasis using a single device. The technology will offer physicians a less invasive endoscopic surgical solution for removing pre-cancerous lesions in the colon, and one which significantly reduces procedure and recovery time as well as generating effective patient outcomes."

 
  Creo Medical Group plc 
 Richard Rees (CFO)                                                    [phone] 
 
 Cenkos Securities                                                     [phone] 
 Stephen Keys / Mark Connelly (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Paul McManus                                                     Mob: [phone] 
 Helen Cresswell                                                  Mob: [phone] 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRABDGDSSGDBGCX

(END) Dow Jones Newswires

April 24, 2019 02:01 ET (06:01 GMT)